These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38590011)

  • 1. Prevalence of massively diluted bone marrow cell samples aspirated from patients with myelodysplastic syndromes (MDS) or suspected of MDS: A retrospective analysis of nationwide samples in Japan.
    Ogata K; Mochimaru Y; Kasai N; Sei K; Kawahara N; Ogata M; Yamamoto Y
    Br J Haematol; 2024 May; 204(5):1856-1861. PubMed ID: 38590011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting the most often used item in the haematological tool box-The extent of haemodilution in bone marrow aspirates.
    Hokland P
    Br J Haematol; 2024 May; 204(5):1593-1594. PubMed ID: 38602310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.
    Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
    Leuk Res; 2015 Feb; 39(2):177-82. PubMed ID: 25533930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
    Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
    Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
    Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Bone marrow aspirate automated counts on hematology analyzers: formulating a scoring system based on hematology parameters, to discriminate reactive versus myelodysplastic syndrome-related bone marrows".
    Tsagarakis NJ; Paterakis G; Papadhimitriou SI; Kritikou-Griva E; Goumakou E; Oudatzis G; Theodorakos I; Vasileiou P
    Int J Lab Hematol; 2019 Aug; 41(4):542-549. PubMed ID: 31102331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts.
    Font P; Loscertales J; Soto C; Ricard P; Novas CM; Martín-Clavero E; López-Rubio M; Garcia-Alonso L; Callejas M; Bermejo A; Benavente C; Ballesteros M; Cedena T; Calbacho M; Urbina R; Villarrubia J; Gil S; Bellón JM; Diez-Martin JL; Villegas A
    Ann Hematol; 2015 Apr; 94(4):565-73. PubMed ID: 25387664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes.
    Lambertenghi-Deliliers G; Annaloro C; Oriani A; Soligo D; Pozzoli E; Polli EE
    Ann Hematol; 1993 Feb; 66(2):85-91. PubMed ID: 8448244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinically relevant possibilities and limits of differential diagnosis of megaloblastic anemia and myelodysplastic syndrome - refractory anemia type in bone marrow biopsies].
    Vašeková P; Szépe P; Marcinek J; Balhárek T; Plank L
    Vnitr Lek; 2016; 62(9):692-697. PubMed ID: 27715070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
    Arenillas L; Calvo X; Luño E; Senent L; Alonso E; Ramos F; Ardanaz MT; Pedro C; Tormo M; Marco V; Montoro J; Díez-Campelo M; Brunet S; Arrizabalaga B; Xicoy B; Andreu R; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
    J Clin Oncol; 2016 Sep; 34(27):3284-92. PubMed ID: 27382099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the bone marrow histology between childhood myelodysplastic syndrome with multilineage dysplasia and refractory cytopenia of childhood without multilineage dysplasia.
    Iwafuchi H; Ito M
    Histopathology; 2019 Jan; 74(2):239-247. PubMed ID: 30062702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome.
    Matarraz S; Teodosio C; Fernandez C; Albors M; Jara-Acevedo M; López A; Gonzalez-Gonzalez M; Gutierrez ML; Flores-Montero J; Cerveró C; Pizarro-Perea M; Paz Garrastazul M; Caballero G; Gutierrez O; Mendez GD; González-Silva M; Laranjeira P; Orfao A
    PLoS One; 2012; 7(8):e44321. PubMed ID: 22952954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma.
    Choi H; Kim Y; Kang D; Kwon A; Kim J; Min Kim J; Park SS; Kim YJ; Min CK; Kim M
    Cell Prolif; 2020 May; 53(5):e12819. PubMed ID: 32372504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS).
    Mohamedali AM; Gäken J; Ahmed M; Malik F; Smith AE; Best S; Mian S; Gaymes T; Ireland R; Kulasekararaj AG; Mufti GJ
    Leukemia; 2015 Sep; 29(9):1928-38. PubMed ID: 25943179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome.
    Mohamedali AM; Alkhatabi H; Kulasekararaj A; Shinde S; Mian S; Malik F; Smith AE; Gäken J; Mufti GJ
    Blood; 2013 Jul; 122(4):567-70. PubMed ID: 23760614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?
    Cherry AM; Slovak ML; Campbell LJ; Chun K; Eclache V; Haase D; Haferlach C; Hildebrandt B; Iqbal AM; Jhanwar SC; Ohyashiki K; Sole F; Vandenberghe P; VanDyke DL; Zhang Y; Dewald GW
    Leuk Res; 2012 Jul; 36(7):832-40. PubMed ID: 22537394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia.
    Matsushima T; Handa H; Yokohama A; Nagasaki J; Koiso H; Kin Y; Tanaka Y; Sakura T; Tsukamoto N; Karasawa M; Itoh K; Hirabayashi H; Sawamura M; Shinonome S; Shimano S; Miyawaki S; Nojima Y; Murakami H
    Blood; 2003 May; 101(9):3386-90. PubMed ID: 12506028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphologic classification of the myelodysplastic syndromes (MDS): combined utilization of bone marrow aspirates and trephine biopsies.
    Bartl R; Frisch B; Baumgart R
    Leuk Res; 1992; 16(1):15-33. PubMed ID: 1732665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.
    Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores-Montero J; Rasillo A; Sayagues JM; Sánchez ML; Bárcena P; Hernandez-Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Laranjeira P; Paiva A; Orfao A
    Cytometry B Clin Cytom; 2010 May; 78(3):154-68. PubMed ID: 20198685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.